Effect of total saponins of "panax notoginseng root" on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats.
OBJECTIVE
the effect of total saponins of "panax notoginseng root" on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats


METHODS
Sprague-Dawley rats were randomly divided into sham-operated, control, TSPN and atorvastatin group. Rat aorta intima in all groups were injured by insertion of domestic balloon catheter into the aortae except sham-operated rats. Drugs were administrated orally from the second day after vascular injury and continued for 14 days. The injured segments of aortae were collected on the sixteenth day after operation to observe the morphological changes of vascular structure and to examine the expressions of proliferating cell nuclear antigen(PCNA), cyclinD1, cyclinE, collagen I(Col-I), fibronect(FN), matrix metalloproteinase-9(MMP-9) and tissue inhibitor metalloproteinase-1(TIMP-1).


RESULTS
TPNS significantly inhibited the vascular intimal hyperplasia. TPNS significantly lowered the expression of PCNA, cyclinE, cyclinD1, FN and MMP-9. TPNS had no significant impacts on the expression of Col-I and TIMP-1.


CONCLUSIONS
Our studies indicated that TSPN could inhibit vessel restenosis after vascular intimal injury, and its mechanisms may be related to the blockage of the excessive proliferation of VSMC, the reduction of ECM protein deposition in the endometrium, and the degradation of ECM protein.
Wu
Lu
L
The Second Affiliated Traditional and Western Medicine Hospital of Hunan University of Traditional Chinese Medicine, Liuyang, Changsha, Hunan, China.
Zhang
Wei
W
Tang
Ying-Hong
YH
Li
Hua
H
Chen
Bei-Yang
BY
Zhang
Guo-Min
GM
Deng
Chang-Qing
CQ
D000818:Animals; D000924:Anticholesteremic Agents; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D000069059:Atorvastatin; D018797:Cell Cycle Proteins / Q000378:metabolism*; D024042:Collagen Type I / Q000378:metabolism; D023903:Coronary Restenosis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D016213:Cyclins / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D005109:Extracellular Matrix / Q000378:metabolism*; D005353:Fibronectins / Q000378:metabolism; D006538:Heptanoic Acids; D006965:Hyperplasia / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D053723:Panax notoginseng / Q000737:chemistry*; D008517:Phytotherapy; D018517:Plant Roots; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011758:Pyrroles; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000494:pharmacology / Q000627:therapeutic use*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
D000924:Anticholesteremic Agents; D018797:Cell Cycle Proteins; D024042:Collagen Type I; D016213:Cyclins; D004365:Drugs, Chinese Herbal; D005353:Fibronectins; D006538:Heptanoic Acids; D018809:Proliferating Cell Nuclear Antigen; D011758:Pyrroles; D012503:Saponins; D019715:Tissue Inhibitor of Metalloproteinase-1; D000069059:Atorvastatin; D020780:Matrix Metalloproteinase 9